Clinical trials: Cervical Cancer Recurrent
Human Papilloma Virus, Cervical Cancer
M7824 in Subjects With HPV Associated Malignancies
Background: In the United States, each year there are more than 30,000 cases of human papillomavirus (HPV) associated cancers. Some of these cancers are often incurable and are not improved by standard therapies.
- Conditions
- Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer
- Trial name
- NCT03427411
- Testing
- M7824
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Papillary Thyroid Carcinoma
Diagnostic Accuracy of Fluorodeoxyglucose-18 PET in the Evaluation of RPTC With Patient's Raised Thyroglobulin Level
This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised…
- Trial name
- NCT07062211
- Where
- Pakistan
- Volunteers
- 39 people
- Sponsor
- Superior University
Head and Neck Squamous Cell Carcinoma (HNSCC)
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in…
- Trial name
- HexAgon-HN (NCT06295731)
- Testing
- INBRX-106, Pembrolizumab
- Where
- 87 sites in United States, Australia and 11 more
- Volunteers
- 410 people
- Sponsor
- Inhibrx Biosciences, Inc
Recurrent Head and Neck Cancer
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
This study will evaluate the clinical activity of the combination of ipilimumab (IPI) -926 in combination with cetuximab in patients with advanced head and neck cancer.
- Trial name
- NCT01255800
- Testing
- IPI-926 and Cetuximab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Squamous Cell Carcinoma of Esophagus
A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
As a 2nd generation EGFR-TKI that irreversibly binds to EGFR receptors, afatinib showed the possibility of superior effects to 1st generation TKIs such as erlotinib and gefitinib.
- Trial name
- NCT02353936
- Testing
- BIBW2992
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Head and Neck Cancer
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
RATIONALE: Diagnostic procedures, such as analysis of tumor tissue and lymph nodes that have been surgically removed, may improve the treatment of patients with cancers of the head and neck.
- Trial name
- NCT00002695
- Testing
- DNA stability analysis, microsatellite instability analysis, mutation analysis
- Where
- 4 sites in United States
- Volunteers
- 530 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
This phase I/II trial studies the side effects and how well bintrafusp alfa and stereotactic body radiation therapy work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has occurred…
- Trial name
- NCT04220775
- Testing
- Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Gastric Cancer
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054457
- Testing
- capecitabine, docetaxel
- Where
- 28 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Nasopharyngeal Carcinoma
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have…
- Trial name
- NCT06259721
- Testing
- Anti-PD1 antibody, nimotuzumab and capecitabine
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Head and Neck Neoplasms
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
This is a late phase II, prospective, multicenter randomized study, to assess the value of early palliative care integrated with the standard oncologic care in patients with Recurrent Metastatic (RM) Head and Neck Cancer (HNC)…
- Trial name
- SupCare (NCT06347185)
- Testing
- Early palliative care, integrated with the standard oncologic care (proactive approach), Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Gene therapy may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have advanced head…
- Trial name
- NCT00009841
- Testing
- EGFR antisense DNA, growth factor antagonist therapy, DC-cholesterol liposome
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pittsburgh
Malignant Neoplasm of Thyroid Gland
Trial on Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery.
Scientific objectives: Primary objective: To assess if the use of IONM can decrease the rates of temporary RLN palsy after thyroid cancer surgery Secondary objectives: To assess if the use of IONM can decrease permanent RLN palsy…
- Trial name
- ACTION (NCT04842994)
- Testing
- IONM tube
- Where
- India
- Volunteers
- 448 people
- Sponsor
- Tata Memorial Hospital
Carcinoma, Squamous Cell of Head and Neck HNSCC
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
The goal of this Phase 2 clinical trial is to learn if adding ruxolitinib to pembrolizumab may improve treatment outcomes in patients with head and neck squamous cell carcinoma (HNSCC) who have increased levels of systemic…
- Trial name
- InflammaSTOP (NCT07840456)
- Testing
- Ruxolitinib, Pembrolizumab
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 66 people
- Sponsor
- University Hospital, Basel, Switzerland
Nasopharyngeal Carcinoma
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of combination of Apatinib and Camrelizumab regimen in treating recurrent or metastatic nasopharyngeal carcinoma patients who were resistant to PD-1 antagonists.
- Trial name
- NCT04548271
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx
Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors
This pilot clinical trial studies freeze-dried black raspberries (BRB) in preventing oral cancer recurrence in high at-risk Appalachian patients previously treated with surgery for oral cancer.
- Conditions
- Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01504932
- Testing
- BRB Lozenge, Survey Administration, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix.
- Trial name
- NCT00031993
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Carcinoma, Maintenance Therapy
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
The aim of this study is to investigate the efficacy and safety of the "capecitabine combined with toripalimab maintenance regimen" in improving the first-line treatment of recurrent and metastatic nasopharyngeal carcinoma after…
- Trial name
- NCT05869227
- Where
- China
- Volunteers
- 166 people
- Sponsor
- XIANG YANQUN
Nasopharyngeal Carcinoma
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this study is to determine the maximal tolerated dose (MTD) of re-irradiation using carbon ion radiotherapy (CIRT) in the treatment of locally recurrent nasopharyngeal cancer (NPC) and to evaluate the efficacy of…
- Trial name
- NCT02569788
- Testing
- Carbon ion radiotherapy (CIRT)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Squamous Cell Carcinoma Of The Head And Neck
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached…
- Trial name
- NCT01488318
- Testing
- Cetuximab, Dasatinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Julie E. Bauman, MD, MPH